Array BioPharma To Present At The Piper Jaffray Annual Healthcare ... ( BOULDER Colo. Nov. 15 2012 /- Ar...)

Array BioPharma To Present At The Piper Jaffray Annual Healthcare Conference

Date:11/15/2012

BOULDER, Colo., Nov. 15, 2012 /PRNewswire/ -- Array BioPharma Inc. (Nasdaq: ARRY) today announced that its Chief Executive Officer, Ron Squarer, will speak at the Piper Jaffray Annual Healthcare Conference in New York City. The public is welcome to participate in the conference through a webcast on the Array BioPharma website.(Logo: http://photos.prnewswire.com/prnh/20121029/LA02195LOGO) Event:Piper Jaffray Annual Health Care ConferencePresenter:Ron Squarer, Chief Executive OfficerDate:Tuesday, November 27, 2012Time:11:30 a.m. Eastern Time Location:The New York Palace, NYWebcast:www.arraybiopharma.comAbout Array BioPharmaArray BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small‑molecule drugs to treat patients afflicted with cancer. Array is evolving into a late-stage development company, with two wholly‑owned programs, ARRY-614 and ARRY-520, and three partnered programs, selumetinib (with AstraZeneca), MEK162 (with Novartis), and danoprevir (with InterMune / Roche), having the potential to begin Phase 3 or pivotal trials by the end of calendar year 2013. For more information on Array, please go to www.arraybiopharma.com.

CONTACT:

Tricia HaugetoArray BioPharma Inc.303-386-1193thaugeto@arraybiopharma.com

SOURCE Array BioPharma Inc.
Copyright©2012 PR Newswire.
All rights reserved

0

GOOD

Post Your Comments:

(Date:5/24/2013)... , May 24, 2013 Solta Medical, Inc. (NASDAQ: ... aesthetics market, today reported Dr. Edward W. Knowlton ... Board of Directors effective immediately. Dr. Knowlton is the founder ... served as a director since 1996. "On behalf ... management team, I would like to thank Ed for his ...

(Date:5/24/2013)... An international roster of experts on malignant pleural ... Santa Monica, Calif. , to discuss their ... a rare form of cancer that results from exposure ... of the chest. Hosted by UCLA and ... Annual International Symposium on Lung-Sparing Therapies for Malignant Pleural ...

(Date:5/24/2013)... Colo. , May 24, 2013 Heska Corporation (NASDAQ: ... diagnostic and specialty products, announced today that Dr. ... officer, and Jason Napolitano , executive vice ... Annual Marcum MicroCap Conference, which is being held May 30, ... the Grand Hyatt Hotel. The Company,s presentation ...

Breaking Medicine Technology:Dr. Edward W. Knowlton Resigns as a Director of Solta Medical, Inc. 2 International Mesothelioma Experts Present Promising New Research Findings at the 3rd Annual International Symposium on Lung-Sparing Therapies for Malignant Pleural Mesothelioma 2 International Mesothelioma Experts Present Promising New Research Findings at the 3rd Annual International Symposium on Lung-Sparing Therapies for Malignant Pleural Mesothelioma 3 Heska Corporation To Present At The Second Annual Marcum LLP MicroCap Conference 2

[0] Dr. Edward W. Knowlton Resigns as a Director of Solta Medical, Inc.[0] International Mesothelioma Experts Present Promising New Research Findings at the 3rd Annual International Symposium on Lung-Sparing Therapies for Malignant Pleural Mesothelioma [0] Heska Corporation To Present At The Second Annual Marcum LLP MicroCap Conference

... & MENLO PARK, Calif.--(BUSINESS WIRE)--Jun,4, 2007 - ... the presentation of data from its Quinamed(R),(amonafide ... a genotypically optimised dose of Quinamed in,heavily ... tumors. The,key outcomes from this study were ...

... in Journal Heart Finds Taxus Stent,Implantation of Multiple Stents ... for Another Procedure, , MIAMI LAKES, Fla., ... analysis of data from the Western Denmark Heart,Registry found ... open a clogged artery were less,likely to need another ...

Cached Medicine Technology:ChemGenex Reports Successful Personalized Dosing of Quinamed at,ASCO 2 ChemGenex Reports Successful Personalized Dosing of Quinamed at,ASCO 3 ChemGenex Reports Successful Personalized Dosing of Quinamed at,ASCO 4 New Study Suggests Better Patient Outcomes with CYPHER,Sirolimus-Eluting Coronary Stent than with Taxus Stent in,Real-World Clinical Settings 2 New Study Suggests Better Patient Outcomes with CYPHER,Sirolimus-Eluting Coronary Stent than with Taxus Stent in,Real-World Clinical Settings 3

ChemGenex Reports Successful Personalized Dosing of Quinamed at,ASCO New Study Suggests Better Patient Outcomes with CYPHER,Sirolimus-Eluting Coronary Stent than with Taxus Stent in,Real-World Clinical Settings

(Date:5/24/2013)... Paris, France: Routinely measuring fractional flow reserve (FFR) ... diagnosis of chest pain leads to significant changes ... according to results from a study reported at ... wire assessment influence management strategy at coronary angiography ... to assess whether routine assessment of FFR in ...

(Date:5/24/2013)... new investigational device - the Helio System (TF-FA) - ... Heart Valve was successfully deployed in all four patients ... in high-risk aortic insufficiency reported at EuroPCR 2013. , ... help stabilise the SAPIEN XT valve for patients with ... captured between the transcatheter heart valve and the dock. ...

(Date:5/24/2013)... valve implantation (TAVI) is effective and safe in Asian ... from a multicentre Asian registry reported at EuroPCR 2013. ... treatment option for selected patients with symptomatic severe aortic ... American or European centres," Paul Chiam, senior consultant cardiologist ... He explained that it is unknown whether the smaller ...

(Date:5/24/2013)... news about youth and diabetes keeps getting worse. The latest ... who develop Type 2 diabetes are at high risk to ... higher rate than people who acquire Type 2 diabetes as ... they seem to be at very high risk for early ... of pediatric endocrinology in the School of Medicine at The ...

(Date:5/24/2013)... discovery at Oregon Health & Science University highlights an ... infected with the highly evasive HIV virus that causes ... this unique approach to develop its own HIV vaccine ... animal studies. This latest research finding will be published ... Science . , "A major challenge in ...

Breaking Medicine News(10 mins):Health News:Diagnostic coronary angiography: Functional flow reserve changes decisions in 25 percent of cases 2 Health News:Feasibility trial reports deployment of new device for TAVI in aortic insufficiency 2 Health News:Registry confirms TAVI efficacy and safety in Asian patients 2 Health News:Youth with type 2 diabetes at much higher risk for heart, kidney disease 2 Health News:OHSU research highlights promising strategy to help vaccines outsmart HIV 2

[0] Diagnostic coronary angiography: Functional flow reserve changes decisions in 25 percent of cases [0] Feasibility trial reports deployment of new device for TAVI in aortic insufficiency [0] Registry confirms TAVI efficacy and safety in Asian patients [0] Youth with type 2 diabetes at much higher risk for heart, kidney disease [0] OHSU research highlights promising strategy to help vaccines outsmart HIV

... million, up 7.6% from the first ... quarter of 2007., - Same ... March 31, 2008 over the corresponding period ended in 2007.,- Cash From Facility ... 19% increase over the first period of 2007, and was $0.41 per ...

... drugs that work by blocking brain molecules similar to ... in young children, according to a new study from ... is known to be an appetite stimulant, and a ... Acomplia) developed by Sanofi-Aventis and awaiting approval for use ...

... The American Academy,of Physician Assistants (AAPA), representing ... U.S., is pleased to join other national,organizations ... Treating Tobacco Use and Dependence: 2008 Update., ... even stronger,evidence to support the efforts of ...

... SAO PAULO, Brazil, May 7 Medial Saude S/A,(BOVESPA: MEDI3) (MEDIAL SAUDE) announces the following webcast:, ... When: Thursday, May 8, 2008 @ 12:00 PM EDT, Where: ... Internet -- Simply log on to the web at the ... Conference call dial-in phone numbers: ...

... a Puzzling Pediatric Tumor--, PHILADELPHIA, May 7 ... for the,first time identified a chromosome region that is ... an often fatal childhood cancer., The investigators found ... of chromosome 6 raises the risk that a child ...

... French . , Ottawa (May 7, 2008) ... today funding from the Canadian Institutes of Health Research ... over $298 million. Minister Clement was joined by Dr. ... Po-Yin Cheung, a neonatologist and CIHR-funded researcher from the ...

Brookdale Announces First Quarter 2008 Results MIT study suggests caution on new anti-obesity drug in kids AAPA Endorses 2008 Public Health Service Guidelines for Treating Tobacco Use and Dependence Webcast Alert: Medial Saude S/A Announces First Quarter 2008 Earnings Conference Call Webcast Researchers Find Gene Location That Gives Rise to Neuroblastoma, an Aggressive Childhood Cancer CIHR news: health research touching lives

... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...

... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...

... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...

Medicine Products:

T-Cell Immunodeficiency Extended Profile T-Cell Clonality Assessment by Restriction Fragment Southern Blot Hybridization, Fluid Syphilis Antibody, IgM by ELISA Susceptibility